PCSK9s are coming: But who will get them?
This article was originally published in Scrip
Executive Summary
FDA watchers would be shocked if US regulators declined to approve the first two applications for proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors –Sanofi's and Regeneron Pharmaceuticals' Praluent (alirocumab), which is up first, with an action date of 24 July, and Amgen's Repatha (evolocumab), whose verdict is anticipated by 27 August.